Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting Multiple Sclerosis

Journal of Neuroimmunology

Volumn 192, Issue 1-2, 2007, Pages 219-225

  Fainardi, Enrico ^a,b   Rizzo, Roberta ^a   Melchiorri, Loredana ^a   Stignani, Marina ^a   Castellazzi, Massimiliano ^a   Caniatti, Maria Luisa ^a   Baldi, Eleonora ^a   Tola, Maria Rosaria ^a   Granieri, Enrico ^a   Baricordi, Olavio Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Cerebrospinal fluid; HLA G5; Multiple Sclerosis; sHLA G1

Indexed keywords

HLA G ANTIGEN; HLA G1 ANTIGEN; HLA G5 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REMISSION; WESTERN BLOTTING;

ADULT; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 36849092473     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.10.002     Document Type: Article

References (28)

1. Carosella E.D., Moreau P., Aractingi S., and Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol. 22 (2001) 553-555
2. + cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur. J. Immunol. 33 (2003) 125-134
3. Fainardi E., Rizzo R., Melchiorri L., Vaghi L., Castellazzi M., Marzola A., Govoni V., Paolino E., Tola M.R., Granieri E., and Baricordi O.R. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. J. Neuroimmunol. 142 (2003) 149-158
4. Fainardi E., Rizzo R., Melchiorri L., Castellazzi M., Paolino E., Tola M.R., Granieri E., and Baricordi O.R. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult. Scler. 12 (2006) 2-12
5. Feger U., Tolosa E., Huang Y.-H., Waschbisch A., Biedermann T., Melms A., and Wiendl H. HLA-G expression defines a novel regulatory T cell subset present in human peripheral blood and sites of inflammation. Blood 110 (2007) 568-577
6. + cells by interacting CD8. J. Immunol. 164 (2000) 6100-6104
7. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354 (2006) 942-955
8. Fuzzi B., Rizzo R., Criscuoli L., Noci I., Melchiorri L., Scarselli B., Bencini E., Menicucci E., and Baricordi O.R. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur. J. Immunol. 32 (2002) 311-315
9. Horuzsko A., Lenfant F., Munn D.H., and Mellor A.L. Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice. Int. Immunol. 13 (2001) 385-394
10. Kanai T., Fujii T., Kozuma S., Yamashita T., Miki A., Kikuchi A., and Taketani Y. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol. Hum. Reprod. 7 (2001) 195-200
11. Kroner A., Grimm A., Johannssen K., Mäurer M., and Wiendl H. The genetic influence of the nonclassical MHC molecules HLA-G on multiple sclerosis. Hum. Immunol. 68 (2007) 422-425
12. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33 (1983) 1444-1452
13. Le Friec G., Laupeze B., Fardel O., Sebti Y., Pangault C., Guilloux V., Beauplet A., Fauchet R., and Amiot L. Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum. Immunol. 64 (2003) 752-761
14. LeMaoult J., Le Discorde M., Rouas-Freiss N., Moreau P., Menier C., McCluskey J., and Carosella E.D. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 62 (2003) 273-284
15. Le Rond S., Azèma C., Krawice-Radanne I., Durrbach A., Guettier C., Carosella E.D., and Rouas-Freiss N. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J. Immunol. 176 (2006) 3266-3276
16. Lila N., Rouas-Freiss N., Dausset J., Carpentier A., and Carosella E.D. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12150-12155
17. Lublin D.F., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
18. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50 (2001) 121-127
19. Mitsdoerffer M., Schreiner B., Kieseier B., Neuhaus O., Dichgans J., Hartung H.-P., Weller M., and Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis. J. Neuroimmunol. 159 (2005) 155-164
20. Poser C.M., Paty D.W., Scheimberger L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for MS: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
21. Rebmann V., Busemann A., Lindemann M., and Grosse-Wilde H. Detection of HLA-G5 secreting cells. Hum. Immunol. 64 (2003) 1017-1024
22. Rebmann V., LeMaoult J., Rouas-Freiss N., Carosella E.D., and Grosse-Wilde H. Report of the Wet Workshop for quantification of soluble HLA-G in Essen, 2004. Hum. Immunol. 66 (2005) 853-863
23. Rebmann V., LeMaoult J., Rouas-Freiss N., Carosella E.D., and Grosse-Wilde H. Quantification and identification of soluble HLA-G isoforms. Tissue Antigens 69 (2007) 143-149
24. Rizzo R., Fuzzi B., Stignani M., Criscuoli L., Melchiorri L., Dabizzi S., Campioni D., Lanza F., Marzola A., Branconi F., Noci I., and Baricordi O.R. Soluble HLA-G molecules in follicular fluid: a tool for oocyte selection in IVF?. J. Reprod. Immunol. 74 (2007) 133-142
25. 1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5249-5254
26. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
27. Wiendl H. HLA-G in the nervous system. Hum. Immunol. 68 (2007) 286-293
28. Wiendl H., Feger U., Mittelbronn M., Jack C., Schreiner B., Stadelmann C., Antel J., Brueck W., Meyermann R., Bar-Or A., Kieseier B.C., and Weller M. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 128 (2005) 2689-2704